Nebius (NBIS) › Analysis

Nebius (NBIS) stock analysis, March 5, 2026: NBIS tests $100 resistance after $18B capex plan, but volume says who wins?

Published March 5, 2026 · NBIS chart, levels and live analysis

Key Updates

Nebius shares recovered +4.42% to $95.22 since the February 28 report, stabilizing above the $91 support level established during the prior correction. The modest rebound occurs against a backdrop of continued near-term volatility, with shares declining -2.62% today and -9.21% over the past five trading days. This choppy price action reflects ongoing market digestion of the company's ambitious $18 billion capital expenditure plan while institutional investors continue rotating into AI infrastructure specialists. The stock remains 33% below its late-2025 peak of $142, consolidating within a $91-$100 range as the market reassesses valuation metrics ahead of the massive capacity expansion.

Current Trend

Year-to-date performance stands at +13.76%, demonstrating resilience despite recent volatility. The stock has established a clear support zone at $91-$92, tested successfully during the late February correction, while facing persistent resistance at the $100 psychological level. Over the past month, shares gained +5.86%, though this masks significant intraday volatility with prices fluctuating between $73 and over $100. The six-month performance of +45.44% and twelve-month surge exceeding 210% underscore the secular AI infrastructure thesis, though the recent consolidation phase suggests investors are demanding proof of execution on the massive capital deployment plan. Current price action indicates a technical consolidation pattern within the $91-$100 range, with the stock trading approximately 5% below the range midpoint.

Investment Thesis

The core investment thesis centers on Nebius's position as a specialized neocloud provider capturing share in the rapidly expanding GPU-as-a-Service market. The company's Q4 2025 earnings demonstrated 355.14% revenue growth over three months ending September 30, 2025, validating the accelerating demand for AI compute infrastructure. Major multi-billion dollar contracts with Microsoft and Meta provide revenue visibility, while the company's full-stack AI cloud platform differentiates it from pure-play infrastructure providers. The $18 billion capital expenditure plan for 2026-2027 represents both the primary growth catalyst and key execution risk, as successful deployment would position Nebius to compete directly with established hyperscalers. At under 2.8x forward price-to-sales, the valuation appears compressed relative to neocloud peers, suggesting the market is pricing in significant execution risk. The thesis depends on management's ability to efficiently deploy capital, secure additional anchor customers, and maintain competitive GPU supply chain access during the industry-wide capacity expansion cycle.

Thesis Status

The investment thesis remains intact but faces a critical validation phase. The Q4 2025 earnings report on February 12, which triggered a +9.2% single-session rally to $98.01, confirmed strong operational momentum with revenue reaching $117.5 million and analyst consensus maintaining a Buy rating with $143.67 average price target (54.68% upside from current levels). However, the subsequent 33% correction from the $142 peak reflects legitimate market concerns about capital efficiency and competitive positioning during the 2026-2027 buildout. Increased institutional ownership in Q1 2026, with hedge funds rotating from Mag 7 stocks into infrastructure specialists, validates the secular thesis while the valuation compression to 2.8x forward P/S creates an asymmetric risk-reward profile. The thesis will be tested over the next 6-12 months as the company executes on facility expansions and demonstrates its ability to convert capacity into contracted revenue. The current consolidation represents a healthy digestion period rather than a fundamental deterioration, provided management delivers on capacity ramp guidance.

Key Drivers

The primary near-term catalyst is execution on the $18 billion capital expenditure plan for 2026-2027, which will determine the company's competitive positioning in the neocloud market. Institutional investor rotation from Mag 7 stocks into infrastructure specialists continues to provide demand support, with hedge fund ownership increasing in Q1 2026. The company's ability to secure additional anchor customers beyond Microsoft and Meta will be critical, as demonstrated by the 9.2% post-earnings rally driven by investor confidence in the GPU-as-a-Service scaling model. Broader market dynamics around action-oriented AI technologies, including developments in Clawdbot, Moltbot, and OpenClaw, are driving demand for underlying infrastructure. The company's diversified business model, including Avride autonomous vehicles, TripleTen edtech, and equity stakes in ClickHouse and Toloka, provides strategic optionality beyond core cloud infrastructure.

Technical Analysis

Nebius is consolidating within a well-defined $91-$100 range after the sharp correction from the $142 late-2025 peak. The $91-$92 level has proven resilient as support, tested successfully during the February 28 decline and holding during subsequent volatility. Resistance remains firmly established at $100, with multiple failed breakout attempts since mid-February. The current price of $95.22 sits in the middle of this range, suggesting equilibrium between buyers and sellers. Short-term momentum indicators show weakness with the -2.62% daily decline and -9.21% five-day performance, though the +4.42% recovery since the last report demonstrates buying interest at lower levels. Volume patterns around the $91 support level indicate institutional accumulation, consistent with the reported hedge fund rotation into the stock. The 50-day moving average likely sits near $95-$97 based on recent price action, providing dynamic support. A decisive break above $100 on strong volume would signal resumption of the uptrend toward the $110-$115 zone, while a breakdown below $91 could trigger a retest of the $73-$80 area seen during earlier volatility. The risk-reward ratio favors patient accumulation within the current range, with the $91 support providing a clear stop-loss reference point.

Bull Case

Bear Case

Get a message when the NBIS picture changes — the agent team watches the levels and the news for you.Create a free account

More NBIS analyses